BDSI · Biodelivery Sciences International Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $166.70M | $156.47M | $111.39M | $15.55M | $61.98M | $15.55M |
| Cost of Revenue | $23.37M | $24.66M | $21.59M | $11.26M | $19.50M | $11.26M |
| Gross Profit | $143.33M | $131.81M | $89.80M | $4.29M | $42.49M | $4.29M |
| R&D | - | $0 | $0 | $4.90M | $13.04M | $18.88M |
| SG&A | $106.21M | $98.83M | $86.06M | $58.60M | $58.87M | $49.34M |
| Total Operating Expenses | $106.21M | $98.83M | $86.06M | $63.51M | $71.91M | $68.22M |
| D&A | $140.0K | $538.0K | $1.85M | $740.0K | $693.0K | $437.0K |
| Operating Income | $37.12M | $32.98M | $3.74M | ($23.65M) | ($29.42M) | ($63.94M) |
| Interest Expense | - | - | $19.04M | $10.19M | $8.58M | $3.27M |
| Income Tax | ($55.24M) | $252.0K | $5.0K | $13.0K | ($15.97M) | $0 |
| Net Income | $84.86M | $25.71M | ($15.30M) | ($33.87M) | $5.29M | ($67.14M) |
| EPS - Basic | $0.85 | $0.26 | ($0.18) | ($0.73) | ($1.25) | - |
| EPS - Diluted | $0.82 | $0.24 | ($0.18) | ($0.73) | ($1.25) | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $114.30M | $111.58M | $63.89M | $43.82M | $21.20M | $32.02M |
| Accounts Receivable | $56.87M | $48.15M | $38.79M | $13.63M | $8.85M | $3.57M |
| Inventory | $23.71M | $17.44M | $11.31M | $5.41M | $6.09M | $3.37M |
| Accounts Payable | $8.11M | $4.21M | $11.70M | $3.17M | $12.24M | $9.40M |
| Current Assets | $202.06M | $182.38M | $117.76M | $66.04M | $39.75M | $43.09M |
| Total Assets | $324.60M | $239.89M | $182.91M | $108.53M | $88.10M | $52.32M |
| Current Liabilities | $82.38M | $52.99M | $53.99M | $21.54M | $26.15M | $19.89M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $136.77M | $131.66M | $113.14M | $78.79M | $79.22M | $69.99M |
| Stockholders' Equity | $187.82M | $108.23M | $69.76M | $29.74M | $8.88M | ($17.66M) |
| Retained Earnings | ($256.02M) | ($340.88M) | ($366.59M) | ($351.29M) | ($305.06M) | ($310.34M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $41.04M | $24.98M | $11.07M | ($53.98M) | ($32.45M) | ($53.98M) |
| Investing Cash Flow | ($6.87M) | ($13.0K) | ($30.76M) | ($405.0K) | ($5.86M) | ($405.0K) |
| Financing Cash Flow | ($31.44M) | $22.73M | $39.76M | $2.85M | $27.49M | $2.85M |
| CapEx | $415.0K | $13.0K | $79.0K | $112.0K | $11.0K | $405.0K |
| Free Cash Flow | $40.62M | $24.97M | $10.99M | ($54.09M) | ($32.46M) | ($54.39M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.0% | 84.2% | 80.6% | 27.6% | 68.5% | 27.6% |
| Operating margin | 22.3% | 21.1% | 3.4% | -152.1% | -47.5% | -411.3% |
| EBITDA margin | 22.4% | 21.4% | 5.0% | -147.4% | -46.3% | -408.5% |
| Net margin | 50.9% | 16.4% | -13.7% | -217.9% | 8.5% | -431.9% |
| Free cash flow margin | 24.4% | 16.0% | 9.9% | -348.0% | -52.4% | -349.8% |
| FCF / Net income | 0.48 | 0.97 | -0.72 | 1.60 | -6.14 | 0.81 |
| R&D / Revenue | - | 0.0% | 0.0% | 31.5% | 21.0% | 121.4% |
| SG&A / Revenue | 63.7% | 63.2% | 77.3% | 377.0% | 95.0% | 317.4% |
| Effective tax rate | -186.5% | 1.0% | - | - | - | - |
| Return on assets | 26.1% | 10.7% | -8.4% | -31.2% | 6.0% | -128.3% |
| Return on equity | 45.2% | 23.8% | -21.9% | -113.9% | 59.5% | 380.1% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.45 | 3.44 | 2.18 | 3.07 | 1.52 | 2.17 |
| Quick ratio | 2.17 | 3.11 | 1.97 | 2.82 | 1.29 | 2.00 |
| Cash ratio | 1.39 | 2.11 | 1.18 | 2.03 | 0.81 | 1.61 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | 0.2x | -2.3x | -3.4x | -19.6x |
| Equity multiplier | 1.73 | 2.22 | 2.62 | 3.65 | 9.92 | -2.96 |
| Liabilities / Assets | 0.42 | 0.55 | 0.62 | 0.73 | 0.90 | 1.34 |
| Efficiency | ||||||
| Asset turnover | 0.51 | 0.65 | 0.61 | 0.14 | 0.70 | 0.30 |
| Inventory turnover | 0.99 | 1.41 | 1.91 | 2.08 | 3.20 | 3.34 |
| Days sales outstanding | 125d | 112d | 127d | 320d | 52d | 84d |
| Days inventory outstanding | 370d | 258d | 191d | 175d | 114d | 109d |
| Days payable outstanding | 127d | 62d | 198d | 103d | 229d | 305d |
| Cash conversion cycle | 368d | 308d | 120d | 393d | -63d | -112d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 6.5% | 40.5% | 616.5% | -74.9% | 298.7% | -67.8% |
| Revenue CAGR (3y) | 120.5% | 36.2% | 92.8% | -31.4% | 16.8% | 11.0% |
| Revenue CAGR (5y) | 60.7% | 26.5% | 23.4% | 6.5% | 2.6% | -24.4% |
| Gross profit growth (YoY) | 8.7% | 46.8% | 1994.2% | -89.9% | 890.9% | -89.3% |
| Operating income growth (YoY) | 12.6% | 782.7% | - | 19.6% | 54.0% | -81.7% |
| Net income growth (YoY) | 230.1% | - | 54.8% | - | - | -78.2% |
| EPS growth (YoY) | 241.7% | - | 75.3% | 41.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 62.7% | 127.1% | - | -66.6% | 40.3% | -1126.9% |
| FCF CAGR (5y) | - | - | 0.8% | - | - | - |
| Book value growth (YoY) | 73.5% | 55.1% | 134.6% | 235.0% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$331.30M totalProduct$164.60M · 49.7%
Belbuca$148.19M · 44.7%
Symproic$16.41M · 5.0%
Royalty$2.10M · 0.6%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
1.04
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BIODELIVERY SCIENCES INTERNATIONAL INC against the 5 most active filers in the same SIC group.